Poland· PL-100080214

Iomeron 300

A iomeprol product containing iomeprolum, registered in Poland by Bracco Imaging Deutschland GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC V08AB10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedIomeron 300ATCV08AB10REGISTER NO.PL-100080214PACKS LISTED7CHECKEDSeptember 27, 2026

Where it is registered

Iomeprol is registered in 14 of 19 countries.

Countries holding a registration under ATC V08AB10 (iomeprol), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Iomeprol · ATC V08AB10

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Iomeprolum
Manufacturer
Bracco Imaging Deutschland GmbH
Country
Poland (PL)
ATC code
V08AB10
ATC class
Iomeprol
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    05909990758517
  • gtin
    05909990758524
  • gtin
    05909990758531
  • gtin
    05909990758548
  • gtin
    05909990758555
  • gtin
    05909990615315
  • gtin
    05909990615322

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Iomeprol in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All iomeprol products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Iomeron
  • Belgium · Iomeron
  • Bulgaria · Iomeron
  • Czechia · Iomeron
  • Germany · Imeron
  • Denmark · Iomeron
  • Spain · Iomeron
  • Finland · Iomeron
  • France · Iomeron
  • United Kingdom (Northern Ireland) · Iomeron
  • Greece · Iomeron
  • Croatia · Iomeron
  • Hungary · Iomeron
  • Ireland · Iomeron
  • Italy · Iomeron
  • Luxembourg · Iomeron
  • Netherlands · Iomeron
  • Norway · Iomeron
  • Portugal · Iomeron
  • Romania · Iomeron
  • Sweden · Iomeron
  • Slovenia · Iomeron
  • Slovakia · Iomeron 150, Iomeron 200

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8d0be55-1807-4509-8ade-6cb9da30b130
GET /v1/drugs/e8d0be55-1807-4509-8ade-6cb9da30b130?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "300 mg jodu/ml",
  "packaging": "05909990758517 ¦ Rp ¦ Skasowane ¦ 12058\n1 amp. 20 ml\n05909990758524 ¦ Rp ¦ 12059\n1 butelka 50 ml\n05909990758531 ¦ Rp ¦ 12060\n1 butelka 100 ml\n05909990758548 ¦ Rp ¦ 12061\n1 butelka 150 ml\n05909990758555 ¦ Rp ¦ 12062\n1 butelka 200 ml\n05909990615315 ¦ Rp ¦ 34223\n1 butelka 500 ml\n05909990615322 ¦ Rp ¦ 44136\n1 fiol. 20 ml",
  "substance": "Iomeprolum 612,4 mg/ml; 300 mg jodu/ml",
  "common_name": "Iomeprolum",
  "pl_product_id": "100080214",
  "pozwolenie_nr": "07585",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about iomeprol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.